As per attachment.

Cfo ResignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹14.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+4.6% vs market

Trading & Distributors peers, median of 132sector+0.0%+3.6% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 3.6 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6-1.0+4.6+0.0+3.6

Next day

+5.4-1.8+7.1+0.0+5.4

-3.2+0.8-4.0+0.9-4.2

+0.0+1.8-1.8+1.6-1.6

+1.8+1.2+0.5+1.5+0.2

-0.3+0.7-1.0+1.4-1.7

-4.3-1.5-2.8+0.0-4.3

15d

+0.0-2.5+2.5-2.9+2.9

+0.0-7.2+7.2-5.9+5.9

-8.8-8.9+0.1-7.2-1.6

+5.4+5.5-0.1+0.5+4.8

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 132Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Iqubal Patel has resigned from the post of Chief Financial Officer and Key Managerial Personnel of Norris Medicines Ltd, effective from the close of business hours on February 3, 2026, citing personal reasons. He held the combined role of Accountant and CFO since January 2022. The company has confirmed it is in the process of appointing a new CFO and will inform the stock exchange in due course. The intimation was filed under SEBI LODR Regulation 30 and signed by Director Vimal D. Shah.

Likely market impact

This is a routine key managerial personnel change due to personal reasons with no stated governance concerns. Investors should watch for the announcement of a new CFO appointment, as a prolonged vacancy in this critical finance role could temporarily affect financial reporting oversight.